Tempus AI had its Relative Strength (RS) Rating upgraded from 89 to 93 Thursday.
This exclusive rating from Investor's Business Daily measures price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
History reveals that the top-performing stocks typically have an 80 or higher RS Rating in the early stages of their moves.
Here Are 3 Keys For Successful Stock Investing
While Tempus AI is not near an ideal buy point right now, see if it manages to form and break out from a proper base.
The company posted 0% EPS growth last quarter. Revenue increased 36%.
The company holds the No. 6 rank among its peers in the Medical-Research Equipment/Services industry group. Champions Oncology, Veracyte and Natera are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
